Koers Hutchison China MediTech Limited London S.E.
Aandelen
KYG4672N1198
Farmaceutische producten
Omzet 2024 * | 681 mln. 0 637 mln. | Omzet 2025 * | 836 mln. 0 782 mln. | Marktkapitalisatie | 3,08 mld. 0 2,88 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -109 mln. - -102 mln. | Nettowinst (verlies) 2025 * | -6 mln. - -5,61 mln. | EV/omzet 2024 * | 4,23 x |
Nettoliquiditeiten 2024 * | 199 mln. 0 186 mln. | Nettoliquiditeiten 2025 * | 306 mln. 0 286 mln. | EV/omzet 2025 * | 3,32 x |
K/w-verhouding 2024 * |
-26,7
x | K/w-verhouding 2025 * |
561
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 52,37% |
Recentste transcriptie over Hutchison China MediTech Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 01-01-05 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 01-07-08 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chi Keung To
CHM | Chairman | 72 | 01-01-00 |
Graeme Jack
BRD | Director/Board Member | 73 | 01-03-17 |
Dan Eldar
BRD | Director/Board Member | 70 | 01-08-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |